Stock Screener App

Frei -

Installieren

6.837

3.30% -0.233

after-market

Handel nachbörslich: 6.95 0.113 +1.65%

Unicycive Therapeutics Inc (UNCY)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten

Important Notice to Long-Term Shareholders of Corcept - GlobeNewswire

UNCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

UNCY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Can Unicycive's OLC Address Hyperphosphatemia's Unmet Need With Its 3P Advantage? - RTTNews

Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Will Unicycive Therapeutics Inc. benefit from current market trendsJuly 2025 Snapshot & Verified Entry Point Signals - mfd.ru

Why is Unicycive Therapeutics Inc. stock going downJuly 2025 Spike Watch & Comprehensive Market Scan Insights - mfd.ru

Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

2026-02-19 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4%Should You Buy? - MarketBeat

2026-02-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com

RA Capital discloses 9.99% Unicycive (UNCY) stake via warrant-linked preferred - Stock Titan

AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI

Will Unicycive Therapeutics Inc. stock go up in YEAR2025 Trade Ideas & Safe Entry Zone Tips - mfd.ru

UNCY Should I Buy - Intellectia AI

2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire

Octagon discloses 1M Unicycive (UNCY) shares, holding under 5% - Stock Titan

Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Unicycive Therapeutics: Speculative Biotech Stock Whipsaws Traders As Wall Street Stays Cautious - AD HOC NEWS

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times

Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire

Unicycive Therapeutics Doubles Stock Sale Agreement - MSN

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha

Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals

Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com

UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times

Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView

Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times

Unicycive Therapeutics Announces FDA Acceptance of - GlobeNewswire

FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World

Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com

2026-01-27 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse

Analysts Set Expectations for UNCY FY2030 Earnings - MarketBeat

Trading Action: Will Unicycive Therapeutics Inc benefit from current market trends2025 Growth vs Value & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire

2026-01-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - accessnewswire.com

Portfolio Shifts: Is VRAX a top pick in the sectorJuly 2025 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn

Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN

We Might See A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Soon - simplywall.st

Unicycive Therapeutics (NASDAQ:UNCY) Trading 1% HigherShould You Buy? - MarketBeat

Will Unicycive Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Fast Moving Trade Plans - ulpravda.ru

Can Unicycive Therapeutics Inc. stock continue upward trendQuarterly Portfolio Review & Capital Efficiency Focused Ideas - Улправда

Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

News | Unicycive Therapeutics leases Mountain View offices - CoStar

RPRX

$45.68

3.69%

MRNA

$53.83

6.87%

ROIV

$29.72

0.68%

BNTX

$101.95

1.78%

INSM

$143.54

4.23%

ONC

$292.94

2.03%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters